Abstracts

Search by keyword or author name.

Showing 852 abstracts.

Pauline Howell, Yuanxi Zou, Anthony Garcia-Prats, Grace Montepiedra, Lisa Aaron, Joanna Moreira, Jerry Nedelman, Elin Svensson, Antonio Lombardi, Maria Beumont, Eugene Sun, Sharon Nachman, Anneke Hesseling, Ethel Weld. IMPAACT 2034: Phase 1 Study of the pharmacokinetics (PK), safety/tolerability and acceptability of a single dose of pretomanid in female children with rifampicin-resistant TB (RR-TB). Presented at: The Union World Conference on Lung Health; 2025 Nov 19.

Conference

The Union World Conference on Lung Health

Study

IMPAACT 2034
Pete Slutzker, Tanya Poovathingal, Nairobi Jones, K. Rivet Amico. IMPAACT 2036: Preliminary Insights from IDIs (Presented at the ViiV Symposium: Beyond Efficacy - What Children and Families Tell Us About Long-Acting Injectable Treatment). Presented at: International Workshop on HIV and Pediatrics; 2026 Jul 25.

Conference

International Workshop on HIV and Pediatrics

Study

IMPAACT 2036
IMPAACT P1066: raltegravir (RAL) safety and efficacy in HIV infected (+) youth two to 18 years of age through week 48. Presented at: XIX International AIDS Conference.

Conference

XIX International AIDS Conference

Study

P1066
D Clarke, E Acosta, A Chain, M Cababasay, J Wang, H Teppler, E Smith, R Hazra, S Popson, B Graham, K Calabrese, Y Bryson , S Spector, M Mirochnick. IMPAACT P1110: Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: Dose-finding study in infants born to mothers receiving raltegravir-containing ART. Presented at: IAS 2018.

Conference

IAS 2018

Study

P1110
S Nachman, E Andersen-Nissen, A Gartland, J Hural, MJ McElrath, Z Shi, J Ishmukhamedov, C DiazGranados, C Worrell, P Jean-Philippe, M Cotton, L Farlie, A Violari, The P1113 Study Team. IMPAACT P1113/Aeras C-015-404: Phase I/II Study of H4-IC31 in BCG-Primed Infants. Presented at: TB Vaccines Fourth global Forum.

Conference

TB Vaccines Fourth global Forum

Study

P1113
Impact of body weight on the risk of low lopinavir/r concentrations during the third trimester of pregnancy in HIV-infected Thai and US Women. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy.

Conference

13th International Workshop on Clinical Pharmacology of HIV Therapy
Minda Nikanjam, Lana Tran, Ellen G. Chadwick, Mutsa Bwakura-Dangarembizi, Carolyn Bolton Moore, Pearl Samson, Stephen A Spector, Nahida Chakhtoura, Patrick Jean-Philippe, Lisa Frenkel, Bonnie Zimmer, Alex Benns, Jennifer Libous, Edmund V. Capparelli. Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age. Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2020; 2020 Sep 28.

Conference

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2020

Study

P1070
Danni Wu, Kristin Baltrusaitis, Teacler Nematadzira, Malinda Kaiyo-Utete, Nahida Chakhtoura, Anne Coletti, Katie McCarthy, Chelsea Krotje, Lameck Chinula, Shahin Lockman, Lynda Stranix-Chibanda, IMPAACT 2010 (VESTED) Study Team. Impact of Dolutegravir and Efavirenz on Maternal Mental Health: Depression, Sleep, and Anxiety Outcomes in the IMPAACT 2010 Study. Presented at: CROI 2025; 2025 Mar 10.

Conference

CROI 2025

Study

IMPAACT 2010
Kunjal Patel, D.Sc., M.P.H., Sue X. Ming, Paige L. Williams, Ph.D., Kevin R. Robertson, Ph.D., James M. Oleske, M.D., George Seage, III, Sc.D., M.P.H. Impact of highly active antiretroviral therapy on the incidence of HIV-encephalopathy among perinatally-infected children and adolescents. Presented at: XVII International AIDS Conference.

Conference

XVII International AIDS Conference
Steven Gortmaker, Ph.D., Michael Hughes, Ph.D., Rebecca Oyomopito, M.S., Joseph S. Cervia, M.D., F.A.C.P., F.A.A.P., Michael T. Brady, M.D., James M. Oleske, M.D. Impact of Introduction of Protease Inhibitor Therapy On Reductions In Mortality Among Children and Youth Infected With HIV-1.